Platelet and megakaryocyte biology in the normal and injured lung
Platelet and megakaryocyte biology in the normal and injured lung
批准号:
9921452
负责人:
MARK ROBERTS LOONEY
金额:
$54.24万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-04-01 至 2021-04-30
关键词:
Acute Lung InjuryAddressAdoptive TransferAdultAnatomyAntibodiesAntigensAttentionBiogenesisBiologyBlood CirculationBlood PlateletsBlood TransfusionBone MarrowCell MaintenanceCellsComplicationDevelopmentEndotheliumEventFlow CytometryHematopoieticHomeostasisHomingHospitalsHumanImmuneImmune responseImmune systemIncidenceInjuryInnate Immune ResponseKnowledgeLabelLeadLocationLungLung InflammationLung TransplantationMHC Class I GenesMeasuresMediatingMegakaryocytesMitochondrial DNAMolecularMorbidity - disease rateMusOrganPathway interactionsPatientsPlasmaPlatelet ActivationPositioning AttributePreventiveProcessProductionPublic HealthRegulationReporterRoleSamplingSiteSorting - Cell MovementTechniquesTestingTherapeutic InterventionThrombopoiesisThromboxane A2TransfusionTransgenic OrganismsUnited Statesbaseblood formationexperimental studyextracellularhuman subjectimprovedinterestintravital microscopylipid mediatorlipoxin A4lung injurymigrationmortalitymouse modelneutrophilnovelorgan injuryreconstitutiontargeted treatmenttool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
A major non-infectious complication from blood transfusions is the development of transfusion-related acute
lung injury (TRALI). Although we have made progress in decreasing the incidence of TRALI through donor
management, it remains the number one cause of transfusion-related mortality in the United States and a
major cause of in-hospital morbidity. In this application, we will study the mechanisms by which activated
platelets promote lung damage in TRALI, and we will also study how the lung in turn is the major organ
involved in platelet biogenesis. In Aim 1, we will determine the mechanisms of lung injury development using
a two-event mouse model of antibody-mediated TRALI. The role of mitochondrial DNA as a novel priming
agent will be tested in the mouse model and in plasma samples from human subjects who developed TRALI.
We will then determine the critical site(s) of cognate antigen expression using a new mouse tool to
conditionally delete MHC Class I in cells of interest. Next, the downstream immune response to TRALI will be
investigated by focusing on platelet-induced neutrophil extracellular trap (NET) formation and novel regulators
of this pathway. By mapping critical determinants of immune priming, cell-specific cognate antigen expression,
and NET-mediated lung barrier disruption, we will improve our understanding of TRALI mechanisms. In Aim 2,
we will turn our attention to the contribution of the lung to platelet biogenesis during homeostasis and lung
injury (TRALI). Platelets are critical to the innate immune response in lung injury, but we also hypothesize that
the lung is a major site of platelet biogenesis. Using fluorescent-reporter mice, intravital microscopy, and flow
cytometry, we will determine the anatomic location and activity of megakaryocytes in the lung. Platelet
production from intravascular megakaryocytes in the lung will be measured during homeostasis and injury.
The function of extravascular megakaryocytes in the lung will be tested using lung transplantation and intravital
microscopy techniques. These experiments will establish the lung as a principle sit of platelet production. In
Aim 3, we will determine the role of the lung as a niche for megakaryocytes and hematopoietic precursors.
Using advanced flow-based sorting, we will test for the presence of hematopoietic precursors in the lung
compared to the bone marrow. The function of these hematopoietic precursors will then be tested using
reconstitution strategies involving lung transplantation and adoptive transfer of flow-sorted cells from the lung.
Finally, the homing or niche-promoting factors influencing lung hematopoietic precursors will be tested. The
results from this proposal will elucidate mechanisms responsible for platelet-mediated lung injury and will
identify novel treatment or preventive pathways. These studies will also establish the functional role of the
normal and injured lung in platelet biogenesis and hematopoietic cell maintenance, which has far-reaching
public health implications.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1182/blood.2020010034
发表时间:
2021-02-04
期刊:
Blood
影响因子:
20.3
作者:
[Cleary SJ, Looney MR]
通讯作者:
Looney MR
Two-event Transfusion-related Acute Lung Injury Mouse Model.
两次输血相关的急性肺损伤小鼠模型。
DOI:
10.21769/bioprotoc.1505
发表时间:
2015
期刊:
Bio-protocol
影响因子:
0.8
作者:
[Ortiz-Muñoz,Guadalupe, Looney,MarkR]
通讯作者:
Looney,MarkR
DOI:
10.21769/bioprotoc.1504
发表时间:
2015
期刊:
Bio-protocol
影响因子:
0.8
作者:
[Ortiz-Muñoz,Guadalupe, Looney,MarkR]
通讯作者:
Looney,MarkR
DOI:
10.1136/thoraxjnl-2016-208571
发表时间:
2017-11
期刊:
Thorax
影响因子:
10
作者:
[Hamid U, Krasnodembskaya A, Fitzgerald M, Shyamsundar M, Kissenpfennig A, Scott C, Lefrancais E, Looney MR, Verghis R, Scott J, Simpson AJ, McNamee J, McAuley DF, O'Kane CM]
通讯作者:
O'Kane CM
DOI:
10.1097/shk.0000000000000745
发表时间:
2017-01
期刊:
Shock (Augusta, Ga.)
影响因子:
--
作者:
[Panka BA, de Grooth HJ, Spoelstra-de Man AM, Looney MR, Tuinman PR]
通讯作者:
Tuinman PR
共 6 条
Immunomodulation by splenic megakaryocytes and platelets in sepsis
-
批准号:10640199
-
项目类别:
-
资助金额:$64.38万
-
财政年份:2022
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Immunomodulation by splenic megakaryocytes and platelets in sepsis
-
批准号:10521976
-
项目类别:
-
资助金额:$62.12万
-
财政年份:2022
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Immunobiology of the normal and injured lung
-
批准号:10542751
-
项目类别:
-
资助金额:$93.19万
-
财政年份:2022
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Immunobiology of the normal and injured lung
-
批准号:10353875
-
项目类别:
-
资助金额:$56.6万
-
财政年份:2022
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Mechanisms and pathogenicity of SARS-CoV-2-induced neutrophil extracellular traps
-
批准号:10490902
-
项目类别:
-
资助金额:$62.33万
-
财政年份:2021
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Mechanisms and pathogenicity of SARS-CoV-2-induced neutrophil extracellular traps
-
批准号:10365868
-
项目类别:
-
资助金额:$62.33万
-
财政年份:2021
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Mechanisms and pathogenicity of SARS-CoV-2-induced neutrophil extracellular traps
-
批准号:10676842
-
项目类别:
-
资助金额:$62.33万
-
财政年份:2021
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Mechanisms of antibody-mediated lung Injury after blood transfusion
-
批准号:10318593
-
项目类别:
-
资助金额:$57.73万
-
财政年份:2019
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Innate Immune Mechanisms of Primary Graft Dysfunction after Lung Transplantation
-
批准号:9006789
-
项目类别:
-
资助金额:$53.63万
-
财政年份:2016
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Fine-tuning the Neutrophilic Response to Pneumonia
-
批准号:9157282
-
项目类别:
-
资助金额:$45.18万
-
财政年份:2016
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Fine-tuning the Neutrophilic Response to Pneumonia
-
批准号:9281669
-
项目类别:
-
资助金额:$45.03万
-
财政年份:2016
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Fine-tuning the Neutrophilic Response to Pneumonia
-
批准号:9491695
-
项目类别:
-
资助金额:$45.03万
-
财政年份:2016
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Mechanisms of acute lung injury from blood transfusions.
-
批准号:8646984
-
项目类别:
-
资助金额:$40.05万
-
财政年份:2011
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Mechanisms of acute lung injury from blood transfusions.
-
批准号:8845595
-
项目类别:
-
资助金额:$39.82万
-
财政年份:2011
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Platelet and megakaryocyte biology in the normal and injured lung
-
批准号:9389831
-
项目类别:
-
资助金额:$54.43万
-
财政年份:2011
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Mechanisms of acute lung injury from blood transfusions.
-
批准号:8087774
-
项目类别:
-
资助金额:$43.26万
-
财政年份:2011
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Mechanisms of acute lung injury from blood transfusions.
-
批准号:8240457
-
项目类别:
-
资助金额:$43.26万
-
财政年份:2011
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Mechanisms of acute lung injury from blood transfusions.
-
批准号:8450695
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2011
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Experimental transfusion-related acute lung injury
-
批准号:7743045
-
项目类别:
-
资助金额:$12.58万
-
财政年份:2006
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
Experimental transfusion-related acute lung injury
-
批准号:7992429
-
项目类别:
-
资助金额:$12.58万
-
财政年份:2006
-
负责人:MARK ROBERTS LOONEY
-
依托单位:
海外基金